Aurobindo Pharma Receives US FDA Approval for Beclomethasone Dipropionate Inhaler
Aurobindo Pharma has received final US FDA approval to manufacture and market Beclomethasone Dipropionate HFA Inhalation Aerosol, a generic equivalent of Teva's QVAR Inhalation Aerosol. This marks Aurobindo's first metered-dose inhaler product, expanding its presence in complex respiratory therapies. The product, intended for asthma maintenance in patients aged five and older, will be produced at its North Carolina facility and is expected to launch in upcoming quarters. The US market for this product is estimated at $301 million through July 2026.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 39/100.
Outlets measured: thefinancialexpress, businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–75/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 15 Sept, 09:40 am. Other outlets followed.